SCHEMBL2773068

SCHEMBL2773068

CCc1cc2c(=O)n(CCN3CCOCC3)c(=O)[nH]c2s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 1/20 0.49
ADRA1A P35348 2/20 0.46
ADRA1B P35368 2/20 0.46
MAPK1 P28482 3/20 0.46
AGTR1 P30556 1/20 0.45
IMPDH2 P12268 1/20 0.45
HSD17B10 Q99714 2/20 0.44
QPCT Q16769 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
GAA P10253 1/20 0.42
POLB P06746 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.41
ADRA1D P25100 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2777526 0.92 MAPK1 (0.46) ALDH1A1LMNAHTTADRA1AADRA1B
SCHEMBL2775955 0.84 ADRA1B (0.44) ALDH1A1LMNAHTTADRA1AADRA1B
SCHEMBL2775379 0.83 ADRA1A (0.43) ALDH1A1LMNAADRA1AADRA1BMAPK1
SCHEMBL2774258 0.80 ALDH1A1 (0.54) ALDH1A1LMNAHTTHSD17B10QPCT
SCHEMBL2773547 0.78 ALDH1A1 (0.52) ALDH1A1LMNAHTTMAPK1HSD17B10
SCHEMBL2775047 0.76 ADORA2B (0.54) ALDH1A1LMNAHTTAGTR1HSD17B10
SCHEMBL2776971 0.74 ALDH1A1 (0.48) ALDH1A1LMNAHTTHSD17B10QPCT
SCHEMBL2777323 0.74 POLB (0.52) ALDH1A1LMNAHTTQPCTMEN1
SCHEMBL2774219 0.74 ALDH1A1 (0.50) ALDH1A1LMNAHTTAGTR1HSD17B10
SCHEMBL2775229 0.73 AGTR1 (0.51) ALDH1A1LMNAHTTAGTR1QPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501750-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501750-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501750-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
EP-2253630-A1 Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (JP) 2010-11-24 EP disclosed
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed
EP-2151440-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF PCSK9, APOB, REN ALDH1A1 1296/4885LMNA 552/4885HTT 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.